论文部分内容阅读
目的:探讨华蟾素注射液联合化疗治疗老年结直肠癌患者近期疗效及其对患者血清肿瘤标志物和免疫功能的影响。方法:选择浙江省中医院新昌分院2015年1月至2017年12月收治的老年结直肠癌患者62例，依据随机数字表法分为观察组31例与对照组31例。对照组患者采用化疗治疗，观察组在对照组基础上结合华蟾素注射液。两组均以21 d为1个周期，连续化疗2 ~ 4个周期。比较两组治疗近期疗效，治疗前后Karnofsky功能状态评分（KPS评分）、血清 肿瘤标志物和免疫功能变化，及毒副反应发生情况。结果:观察组近期治疗总有效率为77.42%（24/31），高于对照组的48.39%（15/31），差异有统计学意义（n χ2=5.599，n P<0.05）。观察组治疗后KPS评分为（87.48 ± 6.57）分，高于对照组的（80.20 ± 6.12）分，差异有统计学意义（n t=4.514，n P<0.05）。观察组治疗后血清癌抗原19-9（CA19-9）、糖类抗原724（CA724）和癌胚抗原（CEA）水平均低于对照组[（3.59 ± 1.02）kU/L比（6.98 ± 1.37）kU/L、（7.38 ± 1.87）μg/L比（9.82 ± 1.42）μg/L、（12.27 ± 2.36）μg/L比（16.57 ± 3.24）μg/L]，差异均有统计学意义（n t=11.051、9.042、10.624，n P<0.05）。观察组治疗后CDn 3+、CDn 4+和CDn 4+/CDn 8+高于对照组[（58.97 ± 3.72）%比（47.31 ± 2.98）%、（38.85 ± 3.25）%比（30.19 ± 2.71）%、1.59 ± 0.18比0.89 ± 0.14]，差异均有统计学意义（n t=13.620、11.394、17.091，n P<0.05）。观察组各项毒副反应发生率均低于对照组（n P<0.05）。n 结论:华蟾素注射液联合化疗治疗老年结直肠癌患者近期疗效明显，可提高患者生存质量，且可降低血清CA19-9、CA724和CEA水平，提高患者免疫功能，毒副反应少。“,”Objective:To investigate the short-term effect of Cinobufacin injection combined with chemotherapy on elderly patients with colorectal cancer and its influence on tumor markers and immune function.Methods:Sixty-two elderly patients with colorectal cancer admitted to Xinchang Branch of Zhejiang Hospital of Traditional Chinese Medicine from January 2015 to December 2017 were randomly divided into observation group (31 cases) and control group (31 cases). Patients in the control group were treated with chemotherapy, while those in the observation group were treated with Cinobufacin injection on the basis of the control group. Two treatment of 21 d was as a cycle, continuous chemotherapy 2-4 cycles. The short-term therapeutic effect, Karnofsky function state score (KPS score), serum tumor markers, immune function and side effects of the two groups were compared before and after treatment.Results:After treatment, the total effective rate of the observation group was 77.42%(24/31), and was higher than that of the control group 48.39%(15/31), there was significant difference (n χ2=5.599, n P<0.05). The KPS scores of the observation group was higher than that of the control group [(87.48 ± 6.57) scores vs. (80.20 ± 6.12) scores], there was significant difference (n t=4.514, n P<0.05). The levels of serum cancer antigen 19-9(CA19-9), carbohydrate antigen 724(CA724) and carcino-embryonic antigen (CEA) in the observation group were lower than those in the control group [(3.59 ± 1.02) kU/L vs. (6.98 ± 1.37) kU/L, (7.38 ± 1.87) μg/L vs.(9.82 ± 1.42) μg/L, (12.27 ± 2.36) μg/L vs.(16.57 ± 3.24) μg/L], there were significant differences (n t=11.051, 9.042, 10.624, n P<0.05). The levels of CDn 3+, CDn 4+ and CDn 4+/CDn 8+ in the observation group were higher than those in the control group [(58.97 ± 3.72)% vs. (47.31 ± 2.98)%, (38.85 ± 3.25)% vs. (30.19 ± 2.71)%, 1.59 ± 0.18 vs. 0.89 ± 0.14], there were significant differences (n t=13.620, 11.394, 17.091, n P<0.05). The incidence of side effects in the observation group was lower than that in the control group (n P<0.05).n Conclusions:Cinobufacin injection combined with chemotherapy can improve the quality of life of elderly patients with colorectal cancer in the near future, reduce the levels of serum CA19-9, CA724 and CEA, improve the immune function of patients, and have fewer side effects.